ES2086529T3 - Sistema transdermico. - Google Patents

Sistema transdermico.

Info

Publication number
ES2086529T3
ES2086529T3 ES91901412T ES91901412T ES2086529T3 ES 2086529 T3 ES2086529 T3 ES 2086529T3 ES 91901412 T ES91901412 T ES 91901412T ES 91901412 T ES91901412 T ES 91901412T ES 2086529 T3 ES2086529 T3 ES 2086529T3
Authority
ES
Spain
Prior art keywords
active substance
transdermic
transdermic system
dissociation
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901412T
Other languages
English (en)
Inventor
Jens Hansen
Birgitte Mollgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2086529T3 publication Critical patent/ES2086529T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exposure Control For Cameras (AREA)
  • Details Of Cameras Including Film Mechanisms (AREA)
  • Studio Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN SISTEMA TRANSDERMICO CON UNA CAPA QUE COMPRENDE UNA SUSTANCIA ACTIVA, AL MENOS PARTE DE LA CUAL SE ENCUENTRA EN FORMA DE UN COMPLEJO DE INCLUSION FORMADO ENTRE UN COMPUESTO CICLO Y LA SUSTANCIA ACTIVA. LA VELOCIDAD DE LIBERACION DEL SISTEMA SE CONTROLA MEDIANTE LA DISOCIACION DEL COMPLEJO.
ES91901412T 1989-12-21 1990-12-12 Sistema transdermico. Expired - Lifetime ES2086529T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904296A SE8904296D0 (sv) 1989-12-21 1989-12-21 Transdermal system

Publications (1)

Publication Number Publication Date
ES2086529T3 true ES2086529T3 (es) 1996-07-01

Family

ID=20377820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91901412T Expired - Lifetime ES2086529T3 (es) 1989-12-21 1990-12-12 Sistema transdermico.

Country Status (11)

Country Link
US (1) US5120546A (es)
EP (1) EP0519926B1 (es)
JP (1) JP3141110B2 (es)
AT (1) ATE137405T1 (es)
AU (1) AU6973591A (es)
DE (1) DE69026837T2 (es)
DK (1) DK0519926T3 (es)
ES (1) ES2086529T3 (es)
GR (1) GR3020436T3 (es)
SE (1) SE8904296D0 (es)
WO (1) WO1991009592A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU212730B (en) * 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733269A (en) * 1996-03-15 1998-03-31 Fuisz Technologies Ltd. Method and kit for positioning transdermal delivery system
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
WO1998017263A1 (en) * 1996-10-25 1998-04-30 Copley Pharmaceutical Inc. Transdermal patch
US6022558A (en) * 1997-07-01 2000-02-08 Hu; Oliver Yoa-Pu Transdermal preparations of oxicams
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6146656A (en) * 1998-01-22 2000-11-14 Nitto Denko Corporation Percutaneous absorption preparation
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
CA2346539C (en) * 1998-10-05 2006-09-12 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
ES2336054T3 (es) 1998-12-18 2010-04-07 Alza Corporation Dispositivo transparente para la administracion transdermica de nicotina.
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
WO2000074661A2 (en) * 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
DE10003767A1 (de) * 2000-01-28 2001-10-04 Beiersdorf Ag Hautfreundliches Wirkstoffpflaster zur transdermalen Verabreichung nichtsteroidaler Antirheumatika
CN1431906A (zh) * 2000-05-31 2003-07-23 日绊株式会社 透皮吸收型甾体外用药
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
US20030206945A1 (en) * 2000-12-20 2003-11-06 Giulio Tarro Sticking plaster for controlled release of natural interferon
DE10141651B4 (de) * 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US6743254B2 (en) * 2002-02-01 2004-06-01 Mentor Corporation Tissue expander with protection against accidental puncture
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
AU2003231571A1 (en) * 2002-04-30 2003-11-17 Mochida Pharmaceutical Co., Ltd. External preparation enhanced in systemic property of vidarabine
US20030215487A1 (en) * 2002-05-17 2003-11-20 Il Yang Pharm Co., Ltd. Republic Of Korea Matrix-type device for the transdermal delivery of testosterone applied to the non-scrotal skin
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
RS20050812A (sr) * 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
CA2534238A1 (en) * 2003-07-28 2005-02-10 Alza Corporation Transdermal warfarin-containing delivery system
JP4160474B2 (ja) * 2003-08-01 2008-10-01 リンテック株式会社 角質改善用積層シート
AU2004287412A1 (en) * 2003-10-28 2005-05-19 Alza Corporation Method and apparatus for reducing the incidence of tobacco use
DE10357321A1 (de) * 2003-12-05 2005-07-21 Tesa Ag Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
US20090130189A1 (en) * 2004-03-19 2009-05-21 Pfizer Health Ab Means for transdermal administration of nicotine
CN101277672A (zh) * 2005-07-29 2008-10-01 通用医疗公司 用于减少皮肤损伤的方法和组合物
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum
US20070248656A1 (en) * 2006-04-25 2007-10-25 Galer Bradley S Topical preparation dispensers and methods of using the same
US20080156821A1 (en) * 2006-04-25 2008-07-03 Bradley Stuart Galer Topical preparation dispensers and methods of using the same
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
EP2121027A2 (en) * 2007-01-17 2009-11-25 Devirex AG Cyclodextrin formulations
DE102007020799A1 (de) 2007-05-03 2008-11-06 Novosis Ag Transdermales therapeutisches System mit Remifentanil
IE20080661A1 (en) * 2008-08-11 2010-03-03 Bk Pharma Systems Ltd Formulations for a two-phase management of wound healing and dressings incorporating such formulations.
BRPI0823254A2 (pt) * 2008-11-11 2015-06-23 Inst Materia Medica Cams Complexos de inclusão de pinocembrina com ciclodextrina ou seus derivados
EP2504039A4 (en) * 2009-11-25 2014-07-02 Univ Loma Linda Med HEMOSTATIC TEXTILE BASED ON CHITOSAN
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
JP5696279B2 (ja) * 2010-12-01 2015-04-08 学校法人自治医科大学 長期徐放型薬剤硬膜外腔留置システム
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
DE102020111668A1 (de) 2020-04-29 2021-11-04 Organoid Technologies Gmbh Naturstoffpad
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
US4661105A (en) * 1981-06-29 1987-04-28 Alza Corporation Medical bandage for administering vasodilator drug
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
JPH06253662A (ja) * 1993-02-26 1994-09-13 Iseki & Co Ltd 脱穀装置

Also Published As

Publication number Publication date
JPH05504895A (ja) 1993-07-29
US5120546A (en) 1992-06-09
EP0519926B1 (en) 1996-05-01
GR3020436T3 (en) 1996-10-31
DK0519926T3 (da) 1996-06-17
EP0519926A1 (en) 1992-12-30
WO1991009592A1 (en) 1991-07-11
DE69026837T2 (de) 1997-01-02
DE69026837D1 (de) 1996-06-05
JP3141110B2 (ja) 2001-03-05
SE8904296D0 (sv) 1989-12-21
AU6973591A (en) 1991-07-24
ATE137405T1 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
ES2086529T3 (es) Sistema transdermico.
AR241008A1 (es) Procedimiento para el montaje de un ascensor y el ascensor obtenido por el mismo''
NL300007I2 (nl) Preparaat voor de gereguleerde afgifte van een werkzame stof.
ES2058725T3 (es) Aplicacion transdermica de 2-amino-6-n-propilamino-4,5,6,7-tetrahidrobenzotiazol.
MX9303585A (es) 3,4-dimetil-2,5,6-tris(p-sulfonatofenil)-1-fosfanorbornadieno, procedimiento para su preparacion y procedimiento para la hidroformilacion de compuestos olefinicamente insaturados.
DE68917496D1 (de) Aktivkontrolle des Zwischenraumes.
MX9203755A (es) Dispositivo de suministro iontoforetico de drogas o agentes terapeuticos, dotado de un adhesivo de electrotransporte.
PT92838A (pt) Dispensing devices powered by hydrogel
DE69014498D1 (de) Hyposensibilisierende wirksame Substanz.
IT9022045A0 (it) Procedimento per rivelare la concentrazione di un ingrediente attivo in un sistema acquoso.
AR240225A1 (es) Composicion insecticida que comprende mas de un compuesto activo.
PT86138A (pt) Processo para a activacao transdermica ou topica utilizando um sistema terapeutico transdermico activado pelo utente
NO164168C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,7,4-triazolforbindelser.
ES2015512A4 (es) Proceso para la preparacion de polialcoholes de polieter con reducida saturacion.
ITMI922961A0 (it) Procedimento per la dealogenazione chimica di composti organici alogenati.
NO902626L (no) Fremgangsmaate for stabilisering av biologisk aktive forbindelser immobilisert paa faste faser.
SE8803935D0 (sv) Laekemedelskomposition
IT8921274V0 (it) Corpo di bobina riutilizzabile.
NL180664C (nl) 1,8-alkyleen-3-carboxy-4-oxo-7-piperazinochinolinederivaten, werkwijze voor de bereiding daarvan en anti-microbiele preparaten die een dergelijke verbinding als werkzame stof bevatten.
DK376082A (da) Insekticid
ES2020233B3 (es) Procedimiento para extraccion de nitrohidroxiaromaticos de soluciones acuosas.
DE68908663D1 (de) Verfahren zur Konservierung wässriger Systeme mit 1-Methyl-3,5,7-triaza-1-azoniatrizyklodekantrijodid.
DE68908350D1 (de) Aluminiumhydroxid vom boehmit-typ, verfahren zu dessen herstellung und das hydroxid als wirksamen bestandteil enthaltendes phosphationen-adsorptionsmittel.
ES2011472B3 (es) Procedimiento para el tratamiento de soluciones acuosas producidas en la carboxilacion de compuestos olefinicos no saturados.
NO892292L (no) Fremgangsmaate for fremstilling av overflateaktive forbindelser.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 519926

Country of ref document: ES